VIA
ACAD icon

Vident Investment Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

Vident Investment Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,608
Closed -$210K – 1150
2021
Q2 		$210K Buy
+8,608
New +$194K 0.01% 1039

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vident Investment Advisory's ACAD Position: Q3 2021 in Review

Vident Investment Advisory sold out of Acadia Pharmaceuticals (ACAD) in Q3 2021, closing a stake of 8,608 shares — an estimated $210K sold.

Vident Investment Advisory first reported a position in ACAD in Q2 2021 and held it in 1 quarter. The position peaked at $210K in Q2 2021. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

  • Vident Investment Advisory reported no remaining Acadia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 8,608 Acadia Pharmaceuticals shares in Q3 2021, an estimated $210K.
  • Vident Investment Advisory first reported a position in Acadia Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Vident Investment Advisory's Acadia Pharmaceuticals position peaked at $210K in Q2 2021.
  • 237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.